CLVLYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 03:08):

Stats
本日の出来高	2 797.00
平均出来高	4 039.00
時価総額	481.22M
Last Dividend	$0.0320 ( 2023-09-07 )
Next Dividend	$0 ( N/A )
P/E	25.95
ATR14	$0 (0.00%)

Clinuvel Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Clinuvel Pharmaceuticals 財務諸表

Annual	2023
収益:	$78.32M
総利益:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
収益:	$78.32M
総利益:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
収益:	$65.72M
総利益:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
収益:	$47.98M
総利益:	$43.26M (90.16 %)
EPS:	$0.502

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0320 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.45 - Increase likely (48.93%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0140	2018-09-20
Last Dividend	$0.0320	2023-09-07
Next Dividend	$0	N/A
Payout Date	2023-10-02
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.45
Div. Directional Score	8.90	--

Next Divdend (Est)
(2024-07-01)

$0.0374 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
YKLTF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
MRPLY	Ex Dividend Junior	2023-07-13	Annually	0.00%
CNPWM	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
STWRY	Ex Dividend Junior	2023-05-19	Annually	0.00%
HLFN	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
ASHTY	Ex Dividend Knight	2023-08-10	Semi-Annually	0.00%
OPHLF	Ex Dividend Knight	2023-09-28	Annually	0.00%
DITTF	Ex Dividend Knight	2023-09-28	Annually	0.00%
TREAY	No Dividend Player	2023-06-26	Annually	0.00%
JAIRF	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.42	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.218	1.500	4.55	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	0.670	1.500	8.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				7.45

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.